SpinalCyte has received US patent number 9,533,024, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves an in vivo bioreactor for cartilage engineering. The in vivo bioreactor will be biodegradable and resorbable and will encase a scaffold and cells. Additionally, the device will also be permeable to oxygen, hermetic to fluid, and can be positioned in a joint in vivo.
With this addition, SpinalCyte’s portfolio now includes 14 patents issued and directly owned by the company, along with 36 patents pending.